California Public Employees Retirement System Has $78.30 Million Stake in Hologic, Inc. (NASDAQ:HOLX)

California Public Employees Retirement System lessened its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 0.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,086,141 shares of the medical equipment provider's stock after selling 4,698 shares during the quarter. California Public Employees Retirement System owned about 0.48% of Hologic worth $78,300,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Brooklyn Investment Group grew its holdings in Hologic by 14.7% in the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider's stock valued at $82,000 after buying an additional 145 shares during the last quarter. Smartleaf Asset Management LLC increased its holdings in shares of Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after purchasing an additional 159 shares during the period. Trivant Custom Portfolio Group LLC raised its position in shares of Hologic by 2.1% during the fourth quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider's stock valued at $602,000 after buying an additional 169 shares during the last quarter. UMB Bank n.a. lifted its stake in shares of Hologic by 4.1% in the fourth quarter. UMB Bank n.a. now owns 4,758 shares of the medical equipment provider's stock valued at $343,000 after buying an additional 188 shares during the period. Finally, Capital Investment Counsel Inc grew its position in Hologic by 3.6% during the fourth quarter. Capital Investment Counsel Inc now owns 5,724 shares of the medical equipment provider's stock worth $413,000 after buying an additional 200 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

HOLX has been the subject of several research reports. Needham & Company LLC downgraded shares of Hologic from a "buy" rating to a "hold" rating and set a $90.00 price target on the stock. in a research note on Monday, February 3rd. Leerink Partnrs cut Hologic from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 6th. Raymond James reissued an "outperform" rating and set a $90.00 price objective (down from $95.00) on shares of Hologic in a report on Thursday, February 6th. Evercore ISI reduced their price target on shares of Hologic from $76.00 to $73.00 and set an "in-line" rating on the stock in a research report on Thursday, February 6th. Finally, Citigroup dropped their price objective on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $84.62.

Hologic Trading Up 1.9 %

Shares of HOLX stock traded up $1.13 on Thursday, hitting $61.69. The stock had a trading volume of 4,596,048 shares, compared to its average volume of 1,821,809. The firm has a market cap of $13.84 billion, a P/E ratio of 19.46, a PEG ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a twelve month low of $58.38 and a twelve month high of $84.67. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The company has a fifty day moving average price of $64.69 and a two-hundred day moving average price of $72.88.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.